The US Food and Drug Administration on Wednesday accepted Gilead Sciences’ twice-yearly injection to forestall HIV—a transfer the corporate hailed as a serious breakthrough within the combat towards the sexually transmitted virus.
Drugs to forestall HIV transmission, referred to as pre-exposure prophylaxis or PrEP, have existed for greater than a decade. But as a result of they usually require taking a day by day capsule, they’ve but to make a major dent in world infections.
“This is a historic day within the decades-long combat towards HIV,” Gilead chairman and chief government Daniel O’Day stated in an announcement.
Lenacapavir, marketed below the model identify Yeztugo, has been proven to cut back the danger of HIV transmission by greater than 99.9% in adults and adolescents—making it functionally akin to a robust vaccine.
The firm performed two massive medical trials. The first, involving greater than 2,000 ladies in sub-Saharan Africa, resulted in a 100% discount in infections and demonstrated superiority over the day by day oral capsule Truvada.
In the second trial, involving over 2,000 males and gender-diverse people, solely two infections had been recorded—a 99.9% prevention charge, once more surpassing Truvada.
Reported unintended effects included injection website reactions, headache, and nausea.
Results from each trials had been revealed in The New England Journal of Medicine, and the journal Science named lenacapavir its 2024 “Breakthrough of the Year.”
Price issues dampen hope
Despite the spectacular outcomes, optimism could also be tempered by the drug’s value—an inventory worth of $28,218 per yr within the United States, Gilead spokeswoman Blair Baumwell advised AFP in an e-mail Wednesday.
An earlier long-acting HIV prevention shot—cabotegravir, which is injected each two months and was accepted by the FDA in 2021—prices tens of 1000’s of {dollars} per yr and has but to make a serious world affect.
Lenacapavir’s present record worth for its beforehand accepted use as a remedy for HIV is $39,000 yearly.
Baumwell stated the $28,000-plus per yr value for lenacapavir as a preventive drug is “in keeping with” these of current PrEP merchandise and that the corporate inspects insurers to cowl it.
“We are working to make Yeztugo accessible for anybody who wants or desires it and count on to see broad insurance coverage protection,” she stated within the e-mail.
Activists are urging Gilead to drastically minimize the value to assist finish the HIV pandemic.
“Even high-income nations won’t be able to afford widescale use of lenacapavir at costs above US $20,000 per yr,” stated Andrew Hill of Liverpool University, who led a crew of chemists and scientists that discovered it may very well be mass-produced and offered for as little as $25 per individual per yr.
“I congratulate Gilead and US companions for advancing this vital innovation,” added Winnie Byanyima, under-secretary-general of the United Nations. “Lenacapavir may very well be the instrument we have to convey new infections below {control}—however solely whether it is priced affordably and made out there to everybody who may gain advantage.”
In October, Gilead signed agreements with six pharmaceutical firms to supply and distribute generic variations of the drug, pending regulatory approval, in 120 low- and middle-income nations.
Because it is going to take time for these nations to start manufacturing, the corporate additionally introduced a separate deal in December with the Global Fund—a world partnership established by the United Nations, alongside the US President’s Emergency Plan for AIDS Relief (PEPFAR) and others—to buy doses for 2 million folks.
However, cuts to the PEPFAR program below President Donald Trump’s administration have forged uncertainty over the way forward for that settlement.
© 2025 AFP
Citation:
US approves Gilead’s twice-yearly injection to forestall HIV ( 18)
19
gilead-yearly-hiv.html
.
. The content material is offered for info functions solely.